17 mg of tirzepatide Injection HomeKit How to take ZEPBOUND injection

The abdomen The abdomen is the most commonly used injection site, and for good reason

Obesity is a major risk factor for T2DM [6, 7]

However, over the next year, initiation slowed and even reversed: with first-time prescribing rates declining 31% by June 2025, reflecting an average month-over-month decrease of 0.004 percentage points

Women may find that they achieve satisfactory appetite control and weight loss at doses that would be considered sub-therapeutic for men

[DOI] [PubMed] [Google Scholar] 144.Ji L, Dong X, Li Y, et al

P4045 - Comparative Risk of Small Intestinal Bacterial Overgrowth (SIBO) Among Patients Using GLP-1 Receptor Agonists: A Real-World Analysis Using TriNetX, ACG 2025 Annual Scientific Meeting Abstracts